• PYR-41: Testing E1 Control of IRF7 Degradation

  2026-09-21

  PYR-41, an inhibitor of Ubiquitin-Activating Enzyme E1, offers a mechanistically focused way to test how ubiquitination influences IRF7 stability and antiviral signaling. This article translates recent IBDV–VP3 findings into practical assay logic while clearly separating established evidence from research hypotheses.

• BV6 and Lysosomal Cell-Death Assay Design

  2026-09-21

  BV6 is an IAP antagonist that supports apoptosis induction in cancer cells and treatment-sensitization studies. This article introduces a lysosome-aware assay framework that distinguishes IAP-dependent signaling from downstream or parallel cell-death events.

• Anlotinib Hydrochloride: From Kinase Map to Assay

  2026-09-20

  Anlotinib hydrochloride is a multi-target tyrosine kinase inhibitor whose value extends beyond VEGFR2 blockade. This guide explains how to interpret its three-receptor mechanism, design orthogonal angiogenesis assays, and separate pathway-specific effects from general cytotoxicity in cancer research.

• PYR-41: E1 Inhibition for Ubiquitin Assays

  2026-09-19

  PYR-41 is an inhibitor of Ubiquitin-Activating Enzyme E1 that suppresses ubiquitin-E1 thioester formation and downstream ubiquitination. Product data support applications in ubiquitin-proteasome system inhibition, NF-κB signaling pathway modulation, and a sepsis inflammation model, while also documenting off-target limitations.

• How p38α Inhibitors Accelerate Dephosphorylation

  2026-09-18

  The reference preprint shows that some kinase inhibitors do more than occupy the p38α active site: they stabilize an activation-loop conformation that makes the phospho-threonine more accessible to the phosphatase WIP1. This dual-action mechanism links kinase inhibition with accelerated dephosphorylation and offers a structure-guided strategy for improving inhibitor selectivity and durability.

• Birinapant (TL32711) for Apoptosis Assays

  2026-09-18

  Birinapant (TL32711) is a mechanistic SMAC mimetic for dissecting IAP-regulated apoptosis, TNF signaling, and TRAIL sensitization. Its strongest applied use is biomarker-guided testing in models where MDM1, p53, or chemoradiotherapy resistance may determine the response.

• Morin and the Energy Logic of Podocyte Protection

  2026-09-17

  Morin is emerging as more than a broadly active flavonoid: in a fructose-driven podocyte model, its inhibition of adenosine 5′-monophosphate deaminase connects purine nucleotide cycling with mitochondrial energy failure. This article translates that mechanism into a practical research strategy, covering assay design, compound handling, translational boundaries, and the opportunity to use Morin as both a mechanistic probe and fluorescent aluminum ion probe.

• Aprotinin: A Protease-Aware RBC Assay Strategy

  2026-09-17

  Aprotinin and bovine pancreatic trypsin inhibitor offer a precise way to interrogate serine protease activity, fibrinolysis, and inflammatory signaling. This article connects protease-control experiments with red blood cell membrane biomechanics while defining what the available evidence does—and does not—support.

• Human iPSC Intestinal Organoids for Pharmacokinetics

  2026-09-16

  The reference study establishes a more accessible route to human iPSC-derived intestinal organoids with long-term expansion, cryopreservation, and subsequent epithelial differentiation. Its enterocyte-containing cultures display cytochrome P450 and transporter activities, supporting a human-relevant platform for oral drug absorption and metabolism studies.

• From CA2 Nets to Translational Assays

  2026-09-16

  The loss of hippocampal CA2 perineuronal nets offers a mechanistic explanation for social-memory impairment in Alzheimer’s disease models. This thought-leadership article translates that insight into an assay-development strategy, while positioning 8-DY547-cGMP as a carefully qualified, orthogonal reagent for exploring cyclic-GMP-linked biology without overstating what the current evidence proves.

• Epigenetic Immune Signatures in Melanoma

  2026-09-15

  Anichini and colleagues compared distinct epigenetic drug classes in melanoma and found that guadecitabine most consistently induced tumor-cell immune programs linked to innate sensing and interferon signaling. The study integrates cell-line profiling, protein validation, patient biopsies, xenograft analysis, and TCGA prognostics to identify epigenetic immune priming as a rational strategy for improving checkpoint-blockade responses.

• Dorsomorphin (Compound C) in AMPK and BMP Assays

  2026-09-15

  Dorsomorphin (Compound C) enables reversible, cell-permeable interrogation of AMPK and BMP-SMAD signaling in metabolic, autophagy, differentiation, and bone-formation models. This workflow-focused guide shows how to separate pathway effects, translate a recent Wnt–glycolysis study into assay design, and troubleshoot solubility, timing, toxicity, and interpretation problems.

• Bile Acid Retention and Immune Escape in MASH-HCC

  2026-09-14

  The reference study identifies a GPR120–FXR/ABCB11–bile acid–NLRC5 pathway that links lipid-associated metabolic dysfunction to impaired MHC-I antigen presentation in MASH-HCC. Its mouse-model experiments suggest that reducing intracellular bile acid retention can restore tumor antigenicity and improve anti-PD-1 responses, while also providing a framework for mechanistic cytokine and immune-cell assays.

• FITC Goat Anti-Rabbit IgG (H+L) Antibody Guide

  2026-09-14

  Explore how the FITC Goat Anti-Rabbit IgG (H+L) Antibody supports pathway-resolved fluorescence assays in DON and lycopene intestinal toxicity research. This guide connects ERK–NLRP3 biology with practical controls, modality selection, and reproducible signal interpretation.

• Heart–Insula Axis Dysregulation in PTSD Mice

  2026-09-13

  The reference study identifies a vagus-dependent heart–insula pathway in which sympathetic cardiac overactivation drives insular cortex hyperactivity and PTSD-like behaviors in mice. By combining isoproterenol modeling, cervical vagotomy, electrophysiology, immunofluorescence, and propranolol rescue, it provides a mechanistic framework for studying neurocardiac signaling rather than treating cardiac and behavioral phenotypes as independent outcomes.

8572 records 1/572 page Next 12345 下5页 Last page